Association of Psoriasis With the Risk of Developing or Dying of Cancer

Abstract

Background: The association between psoriasis and the risk of developing or dying from cancer has garnered significant attention in recent years, as evidenced by a growing body of literature. The exploration of this relationship reveals complex interactions between the chronic inflammatory nature of psoriasis, its treatment modalities, and the incidence of various malignancies. Literature Review: The foundational insights provided by (Beyaert et al., 2013) indicate that patients with severe psoriasis are at an increased risk for certain cancers, particularly lymphoma and non-melanoma skin cancer (NMSC). The case study presented by (Morizane et al., 2018) raises concerns regarding the immunosuppressive nature of systemic treatments, suggesting that such therapies may compromise anti-cancer immunity. This highlights the delicate balance healthcare providers must maintain when treating psoriasis, particularly in patients who may already be at increased risk for cancer. In their systematic review, (Wang et al., 2020) complicate the narrative by noting inconsistencies in the evidence linking psoriasis to NMSC. They advocate for a nuanced understanding of this relationship, particularly given the variations in treatment protocols and patient demographics. Lastly, the comprehensive overview provided by (Bu et al., 2022) emphasizes the notable increase in cancer prevalence among psoriasis patients and highlights gender disparities in risk. The findings suggest that while systemic treatments may carry risks, the severity of psoriasis itself is a significant factor in cancer mortality. Conclusion: In conclusion, the literature presents a complex relationship between psoriasis and cancer risk, shaped by disease severity, treatment modalities, and lifestyle factors. While there is evidence of an increased risk for certain malignancies, particularly skin cancers, it is essential to consider confounding variables and the multifactorial nature of this association. Ongoing research is critical to further delineate these relationships and inform clinical practices regarding the management of psoriasis in patients at risk for cancer.